CHRONIC HEPATITIS B. Discontinuation of nucleos(t)ide analogues (NAs) therapy may be considered exceptionally in:

• - persons without clinical evidence of cirrhosis (or based on APRI score

≤2 in adults);

• - and who can be followed carefully long term for reactivation;
• - and if there is evidence of HBeAg loss and seroconversion to anti-HBe

(in persons initially HBeAg positive) and after completion of at least one additional year of treatment;

• - and in association with persistently normal ALT levels and persistently

undetectable HBV DNA levels (where HBV DNA testing is available). ›› Where HBV DNA testing is not available: Discontinuation of NA therapy may be considered in persons who have evidence of persistent HBsAg loss and after completion of at least one additional year of treatment, regardless of prior HBeAg status